Morningstar

Quest Diagnostics Inc DGX

Morningstar Rating
Unlock
Stock XNYS Rating as of
$154.80 +0.38 (0.25%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Quest Diagnostics Should Shake Off Last of the COVID-19 Disruption in 2024

Debbie S. Wang

Quest Diagnostics is a leading provider of independent diagnostic testing in the United States thanks to its network of roughly 2,300 patient service centers across the country. We think the company's size and cost advantage allow Quest to benefit from several secular trends, including the proliferation of diagnostic tests and greater clinical reliance on personalized therapies. Additionally, we expect that Quest will see a reprieve from Medicare-related pricing pressure as regulators tinker with the method for setting lab test reimbursement rates.

Read Full Report

Price vs Fair Value

View History
DGX is trading at a 539% premium.
Price
$154.80
Fair Value
$132.00
Uncertainty
Medium
1-Star Price
$574.13
5-Star Price
$822.10
Economic Moat
Yvyfzr
Capital Allocation
Kvctscyf

Bulls Say, Bears Say

Bulls

Advances in technology and personalized medicine are increasing the number of complex esoteric and gene-based tests available to patients. These tests generally carry a higher profit margin for Quest.

Bears

If a sizable number of hospital-based labs fail to comply with the data collection and reporting requirements of PAMA, the expected improvement in Medicare reimbursements may fail to materialize in 2025.

Show More

News

View All

Trading Information

Previous Close Price
$154.42
Day Range
$154.46–156.52
52-Week Range
$119.59–159.36
Bid/Ask
$150.34 / $158.05
Market Cap
$17.23 Bil
Volume/Avg
712,319 / 840,226

Key Statistics

Price/Earnings (Normalized)
17.67
Price/Sales
1.86
Dividend Yield (Trailing)
1.89%
Dividend Yield (Forward)
1.94%
Total Yield
3.48%

Company Profile

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Value
Total Number of Employees
48,000
Website
https://www.questdiagnostics.com

Competitors

Valuation

View More
Metric
DGX
SHL
MYGN
Price/Earnings (Normalized)
 17.6724.59526.99
Price/Book Value
 2.601.623.25
Price/Sales
 1.861.422.88
Price/Cash Flow
 12.2611.88—
Price/Earnings
DGX
SHL
MYGN

Financial Strength

Metric
DGX
SHL
MYGN
Quick Ratio
 0.790.861.44
Current Ratio
 1.001.011.96
Interest Coverage
 7.014.49−48.66
Quick Ratio
DGX
SHL
MYGN

Profitability

Metric
DGX
SHL
MYGN
Return on Assets (Normalized)
 7.23%3.75%0.46%
Return on Equity (Normalized)
 15.53%6.67%0.70%
Return on Invested Capital (Normalized)
 9.63%4.07%0.67%
Return on Assets
DGX
SHL
MYGN

Diagnostics & Research Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
VffccxkrwkXvby$234.7 Bil
 Danaher Corp
DHR
FdngbgrcqWcsbqn$198.9 Bil
 IQVIA Holdings Inc
IQV
WtxzjwsZnsngq$42.8 Bil
 Agilent Technologies Inc
A
KsmrndkgYfrg$42.5 Bil
 IDEXX Laboratories Inc
IDXX
QqqdlkzhsCfbd$42.1 Bil
 Mettler-Toledo International Inc
MTD
RtklhctgqvWhrlww$31.4 Bil
 Icon PLC
ICLR
YltchcvWvpjp$23.7 Bil
 Waters Corp
WAT
DgkytpshFymx$21.2 Bil
 Illumina Inc
ILMN
VmsghwxgBvkxmsw$20.7 Bil
 Labcorp Holdings Inc
LH
FzdpxnqyFywfyfz$18.6 Bil

Sponsor Center